Karyotype plus NPM1 Mutation Status Defines a Group of Elderly Patients with AML ( ≥60 Years) who Benefit from Intensive Post‐Induction Consolidation Therapy

This article is protected by copyright. All rights reserved.

Source: American Journal of Hematology - September 18, 2016 Category: Hematology Authors: Wolfgang R. Sperr, Otto Zach, Iris P öll, Susanne Herndlhofer, Paul Knoebl, Ansgar Weltermann, Berthold Streubel, Ulrich Jaeger, Michael Kundi, Peter Valent Tags: Research Article Source Type: research